List of Figures
Figure 1: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Glaucoma (millions), 2016–2023 22
Figure 2: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Age-Related Macular Degeneration (millions), 2016–2023 23
Figure 3: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Macular Edema (millions), 2016–2023 24
Figure 4: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Retinopathy (millions), 2016–2023 25
Figure 5: Ophthalmology, Global, Epidemiology Patterns for Dry Eye Syndrome (millions), 2016–2023 26
Figure 6: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lucentis ($bn), 2006–2023 30
Figure 7: Ophthalmology Therapeutics Market, Global, Annual Revenue for Eylea ($bn), 2011–2023 32
Figure 8: Ophthalmology Therapeutics Market, Global, Annual Revenue for Avastin ($bn), 2006–2023 33
Figure 9: Ophthalmology Therapeutics Market, Global, Annual Revenue for Restasis ($bn), 2006–2023 35
Figure 10: Ophthalmology Therapeutics Market, Global, Annual Revenue for Alphagan ($bn), 2006–2023 36
Figure 11: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lumigan ($bn), 2006–2023 37
Figure 12: Ophthalmology Therapeutics Market, Global, Annual Revenue for Xalatan ($m), 2006–2023 38
Figure 13: Ophthalmology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 39
Figure 14: Ophthalmology Therapeutics Market, Global, Pipeline for Ophthalmology by Stage of Development, Molecule Type and Program Type, 2017 40
Figure 15: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Stage of Development, 2017 41
Figure 16: Ophthalmology Therapeutics Market, Pipeline by Mechanism of Action (%), 2017 42
Figure 17: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Mechanism of Action, 2017 43
Figure 18: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2017 44
Figure 19: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2017 45
Figure 20: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2017 46
Figure 21: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2017 47
Figure 22: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017 48
Figure 23: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2017 49
Figure 24: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2017 50
Figure 25: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2017 51
Figure 26: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2017 52
Figure 27: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2017 52
Figure 28: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2017 53
Figure 29: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2017 54
Figure 30: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006–2017 55
Figure 31: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2017 56
Figure 32: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2017 57
Figure 33: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Mechanism of Action (participants), 2006–2017 58
Figure 34: Ophthalmology, Global, Revenue Forecast for Lampalizumab ($m), 2018–2023 59
Figure 35: Ophthalmology, Global, Revenue Forecast for Fovista ($m), 2017–2023 60
Figure 36: Ophthalmology, Global, Revenue Forecast for Brolucizumab ($m), 2017–2023 61
Figure 37: Ophthalmology, Global, Revenue Forecast for Voretigene Neparvovec ($m), 2017–2023 62
Figure 38: Ophthalmology, Global, Revenue Forecast for Roclatan ($m), 2018–2023 63
Figure 39: Ophthalmology, Global, Revenue Forecast for Abicipar Pegol ($m), 2020–2023 64
Figure 40: Ophthalmology, Global, Market Size ($bn), 2016–2023 65
Figure 41: Ophthalmology, Global, Market Share of Key Products, 2016–2023 68
Figure 42: Ophthalmology, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023 69
Figure 43: Ophthalmology, Global, Annual Revenue Forecast for Angiogenesis Inhibitors ($bn), 2016–2023 70
Figure 44: Ophthalmology, Global, Annual Revenue Forecast for Antihistamines ($m), 2016-2023 71
Figure 45: Ophthalmology, Global, Annual Revenue Forecast for Anti-inflammatories ($m), 2016–2023 72
Figure 46: Ophthalmology, Global, Annual Revenue Forecast for IOP-Lowering Drugs ($bn), 2016–2023 73
Figure 47: Ophthalmology Therapeutics Market, Global, Cluster by Growth and Market Share, 2016–2023 74
Figure 48: Ophthalmology Therapeutics Market, Global, Forecast Market Share by Company (%),2016–2023 77
Figure 49: Ophthalmology, Global, Companies by Compound Annual Growth Rate (%), 2016–2023 78
Figure 50: Ophthalmology, Global, Revenues by Product Type, 2014–2022 79
Figure 51: Ophthalmology, Global, Novartis Annual Revenue Forecast ($m), 2016–2023 80
Figure 52: Ophthalmology, Global, Regeneron Annual Revenue Forecast ($m), 2016–2023 82
Figure 53: Ophthalmology, Global, Roche Annual Revenue Forecast ($m), 2016–2023 84
Figure 54: Ophthalmology, Global, Bayer Annual Revenue Forecast ($m), 2016–2023 85
Figure 55: Ophthalmology, Global, Allergan Annual Revenue Forecast ($m), 2016–2023 87
Figure 56: Ophthalmology, Global, Shire Therapeutics Annual Revenue Forecast ($m), 2016–2023 88
Figure 57: Ophthalmology, Global, Mallinckrodt Therapeutics Annual Revenue Forecast ($m), 2016–2023 89
Figure 58: Ophthalmology, Global, Santen Therapeutics Annual Revenue Forecast ($m), 2016–2023 90
Figure 59: Ophthalmology, Global, Aerie Annual Revenue Forecast ($m), 2016–2023 91
Figure 60: Ophthalmology, Global, Companies by Type, 2017 92
Figure 61: Ophthalmology, Global, High-Activity and Late-Stage Pipeline Developers by Level of Ophthalmology Specialization, 2017 93
Figure 62: Ophthalmology, Global, Proportion of Total Company Revenue Attributed to Ophthalmology, 2016–2023 94
Figure 63: Ophthalmology, Global, Licensing Deals, 2006–2017 96
Figure 64: Ophthalmology Global, Licensing Deals by Indication and Value, 2006–2017 97
Figure 65: Ophthalmology, Global, Licensing Deals, 2006–2017 98
Figure 66: Ophthalmology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2017 99
Figure 67: Ophthalmology, Global, Co-development Deals, 2006–2017 107
Figure 68: Ophthalmology, Global, Co-development Deals, 2006–2017 108
Figure 69: Ophthalmology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006–2017 109
Figure 70: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 1 121
Figure 71: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 2 122
Figure 72: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 3 123
Figure 73: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 4 124
Figure 74: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 5 125
Figure 75: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 6 126
Figure 76: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 7 127
Figure 77: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 8 128
Figure 78: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 9 129